Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 6/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027751 | 0.84 | ADORA2A (0.59) | ADORA2AADORA1ADORA3 | |
| SCHEMBL2019577 | 0.83 | LMNA (0.43) | ADORA2AADORA1PDE2APDE10A | |
| SCHEMBL2021909 | 0.79 | ADORA2A (0.61) | ADORA2AADORA1ADORA3 | |
| SCHEMBL2025321 | 0.78 | ALDH1A1 (0.51) | HSP90AA1HSP90AB1ADORA2A | |
| SCHEMBL2018893 | 0.76 | LMNA (0.42) | HSP90AA1HSP90AB1ADORA2AADORA1ADORA3 | |
| SCHEMBL2022715 | 0.70 | TLR8 (0.45) | ADORA2AADORA1ADORA3 | |
| SCHEMBL3946976 | 0.68 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1KDM1ASCN10A | |
| SCHEMBL2018800 | 0.68 | DHFR (0.46) | ADORA2AADORA1ADORA3 | |
| SCHEMBL18750368 | 0.67 | HSP90AA1 (0.76) | HSP90AA1HSP90AB1PDE2APDE10AKDM1A | |
| SCHEMBL19785375 | 0.66 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1PDE2APDE10AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329705-B2 | Substituted triazolo-pyrazine compounds | ARQULE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | MKI67, TP53, THPO | HSP90AA1 3510/4885HSP90AB1 3313/4885ADORA2A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.